RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To evaluate the occurrence of retinal pigment epithelial atrophy in patients with age-related macular degeneration undergoing anti–vascular endothelial growth factor therapy. Methods: The study is a retrospective review. Eligible were patients with age-related macular degeneration and choroidal neovascular membranes treated with anti–vascular endothelial growth factor between October 2007 and February 2011; they were followed for >3 months, with fundus photographs and fluorescein angiography at baseline and with autofluorescence and near-infrared autofluorescence images at baseline and follow-up. Demographics, visual acuity, the type of choroidal neovascular membranes, the number of treatments performed, and the length of follow-up were recorded. Autofluorescence and near-infrared autofluorescence images were evaluated for the presence or absence of areas of reduced signal. A multilevel logistic regression model was used to investigate the factors that may be associated with “progression of atrophy” at follow-up, which was the primary outcome of this study. Results: Sixty-three patients (72 eyes) were followed for a median of 16 months (range, 3–36 months). Atrophy at baseline was observed in 47% (34/72) of eyes; progression of atrophy occurred in 62% (45/72) of eyes at the last visit. The number of anti–vascular endothelial growth factor injections received was statistically significantly associated with the progression of atrophy at follow-up (odds ratio, 1.35; 95% confidence interval, 1.05–1.73; P = 0.02). Conclusion: Atrophy was frequently observed in patients with age-related macular degeneration and choroidal neovascular membranes undergoing anti–vascular endothelial growth factor therapy. Retinal pigment epithelial atrophy was frequently observed in patients with choroidal neovascular membranes and age-related macular degeneration undergoing anti–vascular endothelial growth factor therapy. Progression of retinal pigment epithelial atrophy occurred commonly during the follow-up and was also associated with the number of anti–vascular endothelial growth factor injections received and the presence of preexisting atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“After monthly regimens, excellent visual outcomes can be obtained, with more than 90% of patients expected to maintain their vision and 30% to 40% to experience visual improvement.(1,2) Alternative strategies to monthly injections are widely used in clinical practice, despite the fact that visual outcomes are not as f…”
Background
Cited by
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Self-citationRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Munk, M. R., Ceklic, L., Ebneter, A., Huf, W., Wolf, S., & Zinkernagel, M. S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13157 · Cited by 107
Metadata
- Authors
- Lois, N., Mcbain, V., Abdelkader, E., Scott, N. W., & Kumari, R.
- Venue
- Retina
- Published
- 2013-01
- Volume
- 33
- Issue
- 1
- Pages
- 13-22
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1973394592
- Cited by
- 88
- References
- 2
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. https://app.cochat.ai/papers/10.1097/iae.0b013e3182657fff
- The paper
- Lois, N., Mcbain, V., Abdelkader, E., Scott, N. W., & Kumari, R. (2013). RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. https://doi.org/10.1097/iae.0b013e3182657fff
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.